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Demyelinated lesions of the central nervous system are characteristic for multiple
sclerosis (MS). Remyelination is not very effective, particular at later stages of the
disease, which results in a chronic neurodegenerative character with worsening of
symptoms. Previously, we have shown that the enzyme Tissue Transglutaminase
(TG2) is downregulated upon differentiation of oligodendrocyte progenitor cells (OPCs)
into myelin-forming oligodendrocytes and that TG2 knock-out mice lag behind in
remyelination after cuprizone-induced demyelination. Here, we examined whether
astrocytic or oligodendroglial TG2 affects OPCs in a cell-specific manner to modulate
their differentiation, and therefore myelination. Our findings indicate that human TG2-
expressing astrocytes did not modulate OPC differentiation and myelination. In contrast,
persistent TG2 expression upon OPC maturation or exogenously added recombinant
TG2 accelerated OPC differentiation and myelin membrane formation. Continuous
exposure of recombinant TG2 to OPCs at different consecutive developmental stages,
however, decreased OPC differentiation and myelin membrane formation, while it
enhanced myelination in dorsal root ganglion neuron-OPC co-cultures. In MS lesions,
TG2 is absent in OPCs, while human OPCs show TG2 immunoreactivity during
brain development. Exposure to the MS-relevant pro-inflammatory cytokine IFN-γ
increased TG2 expression in OPCs and prolonged expression of endogenous TG2 upon
differentiation. However, despite the increased TG2 levels, OPC maturation was not
accelerated, indicating that TG2-mediated OPC differentiation may be counteracted by
other pathways. Together, our data show that TG2, either endogenously expressed,
or exogenously supplied to OPCs, accelerates early OPC differentiation. A better
understanding of the role of TG2 in the OPC differentiation process during MS is of
therapeutic interest to overcome remyelination failure.
Keywords: tissue transglutaminase, oligodendrocyte progenitor cells, multiple sclerosis, remyelination,
astrocytes, differentiation
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central
nervous system (CNS) most often starting in young adults (Hafler, 2004; Compston and
Coles, 2008). Clinical symptoms include impairment of sensory, cognitive and motor functions
(Noseworthy et al., 2000). The pathology of MS is characterized by focal lesions of demyelination
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and infiltration of leukocytes into the CNS due to a functionally
impaired blood-brain-barrier (BBB) (Ortiz et al., 2014). Resident
immune cells in the CNS, i.e., microglia, become activated and
secrete cytokines and chemokines that recruit more immune cells
into the CNS (Huang et al., 2000; Sellebjerg and Sørensen, 2003).
Consequently, axons are demyelinated and oligodendrocytes
(OLGs) are eliminated from MS lesions (Reynolds et al.,
2011). To overcome the damage in the CNS, a regenerative
response is initiated that involves recruitment of oligodendrocyte
progenitor cells (OPCs) toward the demyelinated areas by factors,
primarily produced by lesional microglia and astrocytes (Carroll
and Jennings, 1994; Glezer et al., 2006). OPCs subsequently
interact with demyelinated axons and differentiate into mature
myelinating OLGs (Franklin et al., 1997; Sim et al., 2002; Rhodes
et al., 2006). The remyelination process in MS lesions is, however,
not very effective, in particular at later stages of the disease
(Compston and Coles, 2008; Franklin and ffrench-Constant,
2008; Kuhlmann et al., 2008; Goldschmidt et al., 2009; Kotter
et al., 2011), which results in the chronic neurodegenerative
character of this disease with worsening of symptoms (Lublin
et al., 2014). Even though recently it has been shown that mature
OLGs can contribute to remyelination (Jäkel et al., 2019; Yeung
et al., 2019), there is a clear role of OPCs to differentiate into
myelin producing OLGs to overcome demyelination. However,
in the progressive stage of the disease, approximately 70% of
MS lesions that remain demyelinated contain OPCs, suggesting
a failure of OPC maturation in the majority of MS lesions.
The other 30% of the demyelinated lesions contain few or
no OPCs, indicating failure of proliferation and/or migration
(Lucchinetti et al., 1999; Kuhlmann et al., 2008; Fancy et al., 2010;
Maki et al., 2013).
Tissue Transglutaminase (TG2) is a Ca2+-dependent 78
kD multifunctional enzyme expressed in the CNS, including
neurons, astrocytes, microglia and OPCs (Fesus and Piacentini,
2002; van Strien et al., 2011c; Numinskaya and Belkin, 2012;
Espitia Pinzón et al., 2014). Its functions include the cross-linking
of proteins (Aeschlimann and Thomazy, 2000), the binding to
fibronectin, thereby promoting cell-matrix interactions (Akimov
and Belkin, 2001) and the binding and hydrolysis of GTP
enabling transmembrane signaling in cells (Nakaoka et al.,
1994). These functions are encoded for by different structural
molecular domains of the enzyme (Fesus and Piacentini, 2002).
Of interest is that endogenous TG2 has been shown to
stimulate differentiation of cells including neurons, astrocytes
and neutrophils (Campisi et al., 1992; Tucholski et al., 2001;
Balajthy et al., 2006; Numinskaya and Belkin, 2012). Previous
work from our group indicates that TG2 plays a prominent role
in the timing of differentiation of OPCs into myelin-forming
OLGs, i.e., inhibition of TG2 activity delays OPC differentiation
and TG2 knock-out mice lag behind in remyelination of axons
in the corpus callosum upon cuprizone-induced demyelination
(van Strien et al., 2011a). TG2 immunoreactivity was also found
in activated microglia and hypertrophic astrocytes in active
and chronic active MS lesions (van Strien et al., 2011c; Espitia
Pinzón et al., 2017a), likely induced by inflammatory mediators
that are present. Astrocytes contribute to remyelination failure
in MS. Activated astrocytes proliferate and form a dense
network of hypertrophic cells, known as the astroglial scar,
which is beneficial because it seals of inflammation in the
CNS into focal areas (Williams et al., 2007). However, the scar
also impedes remyelination by inhibiting migration of OPCs
into the lesions (Fawcett and Asher, 1999) and maturation
of OPCs within the lesions (Motavaf et al., 2017). Upon
demyelination, activated astrocytes transiently secrete soluble
factors, such as growth factors and cytokines (Wiese et al.,
2012), and deposit extracellular matrix (ECM) proteins, including
fibronectin and hyaluronan, that prevent OPC maturation
(Back et al., 2005; Stoffels et al., 2013b). In MS lesions,
fibronectin dimers are cross-linked to form aggregates and
hyaluronan is present in its high molecular weight form, and
their persistent presence contribute to the non-permissive nature
of this scar for remyelination and to impaired remyelination
by inhibiting OPC differentiation (Back et al., 2005; Sisková
et al., 2006; Stoffels et al., 2013a). Of interest, astrocyte-derived
TG2 affects fibronectin deposition, but not aggregation upon
demyelination (Espitia Pinzón et al., 2017b), and TG2-positive
astrocytes in MS lesions partly co-localize with fibronectin
(van Strien et al., 2011c).
Based on previous observations that both astrocytes and
OPCs express TG2, we questioned here whether astrocytic or
oligodendroglial TG2 affects OPCs in a cell-specific manner to
modulate their differentiation, and therefore the (re)myelination
process. To this end, we used co-culture systems of astrocytes and
OPCs, and/or neurons or myelinating spinal cord cultures with
an astrocyte feeding layer that expressed human TG2 or that were
treated with recombinant TG2 and studied myelin formation.
Moreover, we examined TG2 immunoreactivity in human OPCs
during development and in MS lesions. We also analyzed the
effect of inflammatory mediators that are present in MS lesions
on TG2 expression in OPCs and considered whether this affected
early OPC differentiation. A better understanding of the role of
either astrocytic or oligodendroglial TG2 in OPC differentiation
is of therapeutic interest to overcome failing remyelination in MS.
MATERIALS AND METHODS
TG2 Lentiviral Transduction
Human wild-type TG2 (hTG2; gift from prof. K. Mehta,
University of Texas, M.D. Anderson Cancer Center, Houston,
TX, United States) and GFP were cloned into the lentiviral
vector pCDH (puro). As a control, “empty” plasmid, i.e.,
pCDH vector, was used (MOCK). For the production of
the lentiviral particles, HEK 293T cells were cultured in a
poly-L-lysine- (PLL, 5 µg/ml, Sigma-Aldrich, St. Louis, MO,
United States) coated 6 well plate at 1.0 × 106 cells per well
(2 ml) in Dulbecco’s Modified Eagle Medium (DMEM, Life
Technologies, Paisley, United Kingdom) supplemented with
10% fetal bovine serum (FBS; Bodinco, Alkmaar, Netherlands),
L-glutamine and penicillin and streptomycin (Life Technologies,
United States). Cells were transfected with the constructs,
i.e., the “empty” pCDH vector or the vectors containing the
human wild-type TG2 or GFP, packaging and envelop plasmids
(VSV-G and CMVdR8.1) via calcium phosphate transfection
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or LipofectamineTM 2000 Transfection Reagent (Invitrogen,
Carlsbad, CA, United States) as described in the manufacturer’s
instructions. At 48 h after transfection, 2 ml of conditioned
medium was collected and filtered through a PVDF membrane
based filter (0.45 µm pore size) and either used immediately or
stored at −80◦C until further use. OPCs and astrocytes were
transduced before the shake-off by exposing the cells overnight
at 37◦C to lentiviral particles and polybrene (8 µg/ml; Sigma-
Aldrich, St. Louis, MO, United States). The cells were left to
recover in DMEM supplemented with 10% FBS (Capricorn
Scientific, Ebsdorfergrund, Germany), L-glutamine, penicillin
and streptomycin for 48 h and selected as described below.
Single Cell Cultures
This study was carried out in accordance with the
recommendations of national and local experimental animal
guidelines and regulations. The protocol was approved by
the Institutional Animal Care and Use Committee of the
University of Groningen (Netherlands). Primary glial cultures
were generated from 1-3-day-old Wistar rats (Charles River)
as previously described (Maier et al., 2005; Bsibsi et al., 2012).
Briefly, after 12 days in culture on PLL-coated 75 cm2 cell
culture flasks (Nalge Nunc, Naperville, IL, United States),
OPCs and astrocytes were isolated via a shake-off procedure.
Contaminating microglia were removed by shaking the flasks at
150 rpm for 1 h at 37◦C on an orbital shaker (Innova 4000, New
Brunswick Scientific, United States).
Oligodendrocytes
Subsequently, flasks were shaken at 240 rpm overnight at
37◦C to detach OPCs. Floating OPCs were further purified
via differential adhesion on non-tissue culture dishes (Greiner
Bio-one) and cultured in PLL-coated plates in defined SATO
medium (Maier et al., 2005) in the presence of platelet-
derived growth factor-AA (PDGF-AA, 10 ng/ml; Peprotech;
London, United Kingdom) and fibroblast growth factor-basic
(FGF-2, 10 ng/ml; Peprotech) to synchronize the OPCs. Cells
were plated at a density of 0.3–0.4 × 106 cells per well (6
well plate, Corning, Lowell, MA, United States) for western
blot analysis. For immunocytochemical studies cells were
plated on 13-mm PLL-coated coverslips (VWR, Amsterdam,
Netherlands) in 24 well plates (Corning) at 3.5 × 105 cells
per well or on PLL-coated 8-well chamber slides (Labtek,
Nunc) at 2.5 × 104 cells per well. After 48 h, differentiation
was induced by growth factor withdrawal and cells were
grown in SATO medium supplemented with 0.5% FBS.
OPCs differentiate via pre-myelinating OLGs (immature
OLGs; 3 days after initiating differentiation) into myelinating
OLGs (mature OLGs; 7 days after initiating differentiation).
Recombinant guinea pig TG2 (gpTG2, Sigma-Aldrich,
50 µg/ml), astrocyte conditioned-medium (1:1 ratio with
SATO), and rat recombinant tumor necrosis factor (TNF)-α
(Peprotech, 10 ng/ml), rat recombinant interleukin (IL)-1β
(Peprotech, 10 ng/ml) or rat recombinant interferon (IFN)-γ
(Peprotech, 500 U/ml) were added at the indicated stages of
OLG development.
Astrocytes
Astrocytes were obtained by adding trypsin to the remaining
monolayer of cells. Subsequently, the astrocytes were cultured in
162 cm2 flasks (Corning Costar, Lowell, MA, United States) in
DMEM supplemented with heat-inactivated 10% FBS. To obtain
astrocyte-conditioned medium from control and transduced
cells, astrocytes were cultured in a 6 well plate (1 × 106 cells
per well) in DMEM supplemented with heat-inactivated 10%
FBS. After 24 h, medium was replaced with 1 ml SATO medium
containing 0.5% FBS. After 24 h, medium was collected and
filtered through a 0.45 µm filter and stored at−20◦C until further
use. For spinal cord cultures, control and transduced astrocytes
were plated on 13-mm PLL-coated coverslips in a 24 well plate
(7.0 × 104 cells per well) to form an astrocyte monolayer in
3 days. For western blot analysis, cells were plated on a 6-well
plate at 0.3–0.4× 106 cells per well and collected after 48 h.
Myelinating Co-cultures
Myelinating Spinal Cord Cultures
Myelinating spinal cord cultures were generated from 15-
day-old Wistar rat embryo’s (Charles River) as described
before (Sorensen et al., 2008), with minor modifications.
Briefly, after removal of meninges, the isolated spinal cords
were minced and enzymatically digested. Tissue digestion
was stopped and cells were triturated and centrifuged at
1,000 rpm for 5 min. The cell pellet was resuspended
in plating medium [PM: 50% DMEM (Life Technologies,
United States), 25% horse serum (Invitrogen), 25% HBSS
(Life Technologies, United States) and 2 mM glutamin], and
cells were cultured on 13-mm coverslips in a 24-well plate
with the indicated astrocyte monolayer (control or transduced)
at a density of 2.0 × 105 cells/coverslip (500 µl/well).
After 2 h, 500 µl of differentiation medium [DM: DMEM
supplemented with 1 mg/ml holotransferrin (Sigma-Aldrich,
United States), 20 mM putrescine (Sigma-Aldrich, United States),
4 µM progesterone (Sigma-Aldrich, United States), 6 µM
selenium (Sigma-Aldrich, United States), 10 ng/ml insulin
(Sigma-Aldrich, United States)] was added. Half of the
medium was replaced every second day with fresh DM. After
12 days in vitro (div), insulin was omitted from DM, and
cultures were treated with vehicle (phosphate buffered saline,
PBS) or 50 µg/ml gpTG2. gpTG2 was added upon each
medium change, i.e., every 2 days. The cultures were analyzed
at 26–28 div.
Myelinating DRGN-OPC Co-cultures
Primary rat dorsal root ganglia neurons (DRGNs) were isolated
from 15-days-old Wistar rat embryo’s (Charles River), as
described before (Chan et al., 2004; Stancic et al., 2012), with
minor modifications. Dissociated DRGNs were plated as 40 µl
drops at a density of 6 × 104 cells on 13 mm coverslips
(0.5 ml) that were pre-coated with PLL, followed by growth-
factor-reduced matrigel (1:40 dilution; BD Bioscience). OPCs
(control or transduced) were seeded onto DRGNs after 16–
21 div at a 1:1 ratio in DMEM supplemented with 1% ITS
supplement (Sigma-Aldrich, United States), 0.25% FBS, D+-
glucose (4 mg/ml, Sigma-Aldrich, United States), L-glutamine
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and penicillin and streptomycin. After 2 days in co-culture,
the cultures were treated with vehicle (PBS) or 50 µg/ml
gpTG2. Co-cultures were maintained for up to 14 days with
medium changes at every third day. GpTG2 was added
upon medium changes.
Human Material
In compliance with local and national ethical and legal guidelines,
approval by an ethics committee for the use of post-mortem
human material was not required. We did obtain written
informed consent for brain autopsy and the use of brain tissue
and clinical information for scientific research by either the donor
or the next of kin.
MS Lesions
Post-mortem human (sub)cortical tissue was obtained from
Netherlands Brain Bank (NBB, Amsterdam, Netherlands).
Formalin-fixed, paraffin-embedded tissue sections containing
chronic active white matter lesions or remyelinating lesions were
included from 3 clinically diagnosed and neuropathologically
verified MS patients (age range: 41–53 years).
Human Cerebellum
Human tissue was obtained from the department of Pathology
at the Amsterdam UMC, VU University Amsterdam, after
post-mortem examination. Formalin-fixed, paraffin-embedded
tissue sections containing human cerebellum tissue at gestational





Paraformaldehyde (4% PFA, Merck) fixed cells were
permeabilized with ice-cold methanol for 10 min. After a
30-min block with 4% bovine serum albumin (BSA), cells
were incubated for 60 min at room temperature (RT) with
primary antibodies (see Table 1), i.e., anti-myelin basic protein
(MBP) (1:250, Serotec, Oxford, United Kingdom) or anti-TG2
(1:500, Ab2, Labvision, Fremont, CA, United States) diluted
in 4% BSA in PBS. Next, the cells were rinsed with PBS and
incubated for 25 min with appropriate TRITC-conjugated
secondary antibody (1:50, diluted in 4% BSA in PBS; Jackson
ImmunoResearch, Westgrove, PA, United States). Nuclei were
stained with DAPI (1 µg/ml, Sigma-Aldrich, United States),
and mounting medium (Dako, Heverlee, Belgium) was added
to prevent image fading. The cells were analyzed with a
conventional fluorescence microscope (Olympus ProVis AX70
or Leica DMI 6000 B). OLGs were characterized by morphology,
i.e., cells with a typical astrocytic morphology were excluded,
and in each experiment at least 250 cells were scored as either
MBP-positive or MBP-negative (“differentiation”). In addition,
positive cells bearing MBP-positive membranous structures
spread between the cellular processes were identified as myelin
membrane-forming, irrespective of the extent of membrane
formation (“myelination”).
Myelinating Cultures
Cultures were fixed at the indicated time points in 4% PFA
for 15 min, washed with PBS and incubated at RT in 0.5%
Triton X-100 (TX-100) in 5% normal goat serum (NGS) for
40 min. After PBS washing, the cells were incubated for 2 h
at RT with primary antibodies (see Table 1), i.e., anti-MBP
(1:250) and anti-neurofilament-H (1:5,000, EnCor Biotechnology
Inc., Gainesville, FL, United States) diluted in 2% NGS in PBS.
Staining was visualized by an incubation for 30 min at RT
with appropriate Alexa-conjugated secondary antibodies diluted
in 2% NGS (1:500, Invitrogen, United States). Coverslips were
mounted in mounting media. All analyses were performed
using a confocal laser scan microscope (Leica SP8 AOBS
CLSM, Leica Microsystems, Heidelberg, Germany) equipped
with Leica Confocal Software. Fluorescence images were acquired
sequentially and processed using Adobe Photoshop CS3 (Adobe
Systems, San Jose, CA, United States). Data were obtained
from 3 independent experiments, while in each experiment 4–
5 images at 20x magnifications per coverslip and 1–2 coverslips
per condition were analyzed. To quantify the percentage of
myelinated axons, axonal density (neurofilament staining) was
first measured in ImageJ as a percentage of the total area of
the image. In order to exclude immunoreactivity associated
with OLG cell bodies, myelination was manually traced in
Adobe Photoshop CS3. The percentage of myelinated axons was
calculated as an area in pixels in each image occupied by both
myelin and axons divided by the axonal density.
MS Brain Material
After rapid autopsy (mean postmortem delay: 7.4 h) tissue
samples were fixed in 10% formalin for 30 days and embedded
in paraffin. Sections (10 µm) were cut and mounted on
positively charged glass slides (Menzel-Glaser SuperFrost plus,
Braunschweig, Germany), and dried overnight at 37◦C. Upon
use, sections were heated on a hot plate for 30 min at 58◦C, before
they were deparaffinized in xylene-replacement (Sigma-Aldrich),
and rehydrated through a series of 100, 98, 80, and 70% ethanol
and distilled water. For subsequent antigen retrieval, sections
were rinsed in 0.01 M citrate buffer (pH 6.0) and subsequently
heated in a steam cooker for 30 min in the same buffer. After
antigen retrieval, the sections were allowed to regain RT, rinsed
in Tris-buffered saline (TBS), and incubated for 20 min in TBS
containing 0.3% hydrogen peroxidase and 0.1% sodiumazide.
Non-specific binding sites were blocked with 3% BSA in TBS-T
(blocking solution) for 30 min at RT. Subsequently, sections were
incubated overnight at 4◦C with primary antibodies (see Table 1),
i.e., mouse anti-TG2 (ab1, 1:200, Neomarkers) and rabbit anti-
Olig2 (1:400, Millipore), diluted in blocking solution. The next
day, sections were washed in TBS and incubated for 30 min at
RT in Alkaline Phosphatase (AP) labeled rabbit IgG Polymer
Reagent (ImmPRESSTM, Vector Laboratories, Burlingame, CA,
United States) washed in TBS and incubated for 30 min at RT
in horseradish peroxidase (HRP) labeled mouse IgG Polymer
Reagent (Envision, DAKO). Sections were washed again in TBS
and incubated for 20 min in Liquid Permanent Red (LPR, DAKO)
as a chromogen to stain for Olig2. After several washes in TBS,
sections were incubated for 20 min with Vector SG (3 drops in
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TABLE 1 | Primary antibodies used during immunohistochemistry, immunocytochemistry and western blot analysis.
Antibody Manufacturer Species Dilution IHC/ICC Dilution western blot
Anti-MBP Serotec Rat 1:250 n.a.
Anti-TG2 (Ab1) Neomarkers Mouse 1:200 n.a.
Anti-TG2 (Ab2) Labvision Mouse 1:500 n.a.
Anti-TG2 (Ab3) Labvision Mouse 1:500 1:1,000
Anti-neurofilament-H EnCor Biotechnology Chicken 1:5,000 n.a.
Anti-Olig2 Millipore Rabbit 1:400 n.a.
Anti-PLP Biorad Mouse 1:500 n.a.
Anti-MHC-II (clone LN3) Pierce Mouse 1:1,000 n.a.
Anti-PDGFRα R&D systems Goat 1:100 n.a.
Anti-actin Sigma-Aldrich Mouse n.a. 1:1,000
n.a., not applicable; IHC/ICC, immunohistochemistry/immunocytochemistry.
5 ml PBS with 3 drops of hydrogen peroxide, Vector Laboratories,
Burlingame, CA, United States) as a chromogen to stain for TG2.
Sections were washed in Tris–HCL and running water and were
allowed to dry for 1 h at 37◦C. Sections were cleared in xylene and
coverslipped in Entellan (Merck, Darmstadt, Germany).
In addition, the lesions present in MS tissue were defined
by the loss of myelin as observed by proteolipid protein (PLP),
a marker of myelin, and the immunological activity status
by major histocompatibility complex (MHC) class II staining.
Upon use, sections were heated on a hot plate for 30 min at
56◦C, before they were deparaffinized in xylene-replacement
(Sigma-Aldrich, United States), and rehydrated through a series
of 100, 96, 90, 80, and 70% ethanol and distilled water. For
subsequent antigen retrieval, sections were rinsed in Tris–EDTA
buffer (pH 9.0) and subsequently heated in a steam cooker
for 30 min in the same buffer. After antigen retrieval, the
sections were allowed to regain RT, rinsed in TBS, and incubated
for 15 min in TBS containing 1% hydrogen peroxidase and
0.1% sodiumazide. Non-specific binding sites were blocked with
5% non-fat dried milk (Campina) in TBS-T for 20 min at
RT. Subsequently, sections were incubated overnight at 4◦C
with primary antibodies (see Table 1), i.e., anti-PLP (1:500,
Biorad) or anti-MHC-II (1:1,000, clone LN3, Pierce), diluted
in blocking solution to, respectively, identify myelin staining
and MHC-II positive monocytes/macrophages or microglia.
The next day, sections were washed in TBS and incubated
for 2 h at RT with corresponding biotinylated IgG’s (1:400;
Jackson ImmunoResearch) in TBS-T. Sections were washed in
TBS and incubated with HRP-labeled avidin-biotin complex
(ABC complex, 1:400, Vector Laboratories, Burlingame, CA,
United States) in TBS-T for 1 h at RT. Sections were washed
with TBS and Tris–HCl. Peroxidase activity was visualized using
3,3-diaminobenzidine (DAB, Sigma-Aldrich, St. Louis, MO,
United States) as a chromogen. Sections were washed with Tris–
HCl running tap water. Finally, sections were counterstained
with haematoxylin and washed in running tap water. After
dehydration in graded ethanol solutions, sections were cleared
in xylene and coverslipped in Entellan. All sections were
examined on a Leica DM5000B microscope equipped with a
Nuance Multispectral Imaging System (Perkin Elmer Inc., MA,
United States). Negative controls were performed by omitting the
primary antibody resulting in no immunohistochemical signal
(data not shown).
Human Cerebellum
Formalin-fixed paraffin embedded tissue sections (6 µm) of
human cerebellum obtained at gestational week 28 till post-
partum month 2 (n = 8) were used to determine the
presence of TG2 in OPCs. The sections were deparaffinized,
rehydrated, and pre-treated with citrate buffer (pH 6.0) for
antigen retrieval. Subsequently, the sections were co-incubated
overnight at 4◦C with primary antibodies (see Table 1), i.e., anti-
TG2 (1:500, Ab3, Labvision) and anti-platelet-derived growth
factor receptor (PDGFR)α (1:100, R&D systems, Abingdon,
United Kingdom). After rinsing the sections with TBS, the
sections were co-incubated with appropriate fluorescently labeled
secondary antibody to detect PDGFRα (1:400, Invitrogen,
United States) and TG2 (1:400, Invitrogen) immunoreactivity.
Sections were embedded in Vectashield mounting medium
(Vector Laboratories, Burlingame, CA, United States) and
examined on a Leica confocal laser scanning microscope (Leica,
Rijswijk, Netherlands).
Western Blot Analysis
Cells were washed several times with PBS (pH 7.4), harvested
by scraping, and centrifuged for 7 min at 7,000 rpm at RT.
Pellets were lysed in TNE lysis buffer (50 mM Tris–HCl,
5 mM EDTA, 150 mM NaCl, 1% Triton X-100, and protease
inhibitor cocktail; Complete Mini; Roche Diagnostics GmbH),
pH 7.4). Protein concentrations were determined in a Bio-
Rad DC protein assay (Bio-Rad, Hercules, CA, United States)
using BSA as a standard. Equal amounts of proteins (20 µg
for astrocytes and 30 µg for OLGs) were diluted with reducing
sample buffer and heated for 5 min at 98◦C. Proteins were
separated by 10% SDS-PAGE and transferred to an Immobilon-
FL transfer membrane (Millipore, Bedford, MA, United States)
using a wet blotting system (Biorad) and glycine-Tris-methanol
buffer. The membranes were rinsed with PBS and incubated
for 1 h in blocking solution (Li-Cor Biosciences, Lincoln, NE,
United States). After washing with PBS containing 0.1% Tween-
20, the membranes were incubated overnight with primary
antibodies (see Table 1; TG2, 1:1,000, Ab3, Labvision; actin,
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1:1,000, Sigma-Aldrich, United States) diluted in 50% blocking
solution in PBS containing 0.1% Tween-20. After washing with
PBS containing 0.1% Tween-20, the membranes were incubated
for 1 h with appropriate IRDye-conjugated antibodies (1:5,000,
Li-Cor Biosciences; IRDye) and washed with PBS containing
0.1% Tween-20. The signals were detected using the Odyssey
Infrared Imaging System and software (Li-Cor Biosciences,
United States) and analyzed in Scion image software (Scion
Corporation, Maryland, United States).
Statistical Analysis
Cell data were expressed relative to vehicle-treated (PBS or
MOCK-transduced) control cells, which were set to 100% in each
independent experiment. Statistical analysis was performed in
IBM SPSS software, version 20.0 (IBM Corp, NY, United States).
The Shapiro-Wilk procedure was first applied to test for a normal
distribution of the data. When normally distributed, the one
sample t-test was used when a single treatment was compared
to a control group. Multiple group comparisons of data were
performed using one-way ANOVA followed by Dunnett’s post hoc
test for multiple comparisons compared to the control groups.
Alternatively, when the data were not normally distributed
(for DRGN-OPC co-cultures after lentiviral upregulation of
TG2 in OPCs), a Kruskal–Wallis test was performed followed
by a Mann–Whitney U post hoc analysis. Holm’s sequential
Bonferroni correction was used to account for multiple testing
during non-parametric testing. Data represent means of at least
three independent experiments + standard error of the mean
(SEM). Statistical differences were indicated with ∗P < 0.05,
∗∗P < 0.01 or ∗∗∗P < 0.001.
RESULTS
Human TG2 Expression in Astrocytes
Does Not Significantly Affect OPC
Differentiation and Myelin Membrane
Formation
To examine whether the observed delay in remyelination
in TG2 –/– mice (van Strien et al., 2011a) is an indirect
effect of astrocytes on OPC differentiation, the effect on OPC
differentiation of conditioned medium derived from astrocytes
expressing wild-type hTG2 was examined. First, we showed that
MOCK- and GFP-transduced cells only express endogenous
78 kDa rat TG2, whereas in hTG2-transduced astrocytes hTG2
appeared at a slightly higher molecular weight than endogenous
rat TG2 in TG2-transduced cells (Figure 1A, indicated by
an arrow and an arrowhead, respectively, see Supplementary
Figure 1 for full blot). The percentage of hTG2 in TG2-
transduced cells relative to endogenous TG2 was 22.0% ± 0.7%.
Remarkably, total TG2 expression levels were similar between
hTG2- and GFP- and MOCK-transduced astrocytes, indicating
that astrocytes compensated for hTG2 expression by reducing
endogenous TG2 levels. Notably, in MOCK- and GFP-
transduced astrocytes, but not hTG2-transduced cells, an
additional TG2-reactive band at approximately 75 kDa was
visible. This has been shown by others as well (Kumar and Mehta,
2012; Boroughs et al., 2014) and may represent endogenous TG2
protein that is truncated at the 3′ end (Antonyak et al., 2006).
As astrocytes affect OPC maturation indirectly through
astrocyte-derived secreted factors, which may include secreted
TG2 (Adamczyk et al., 2015), the effect of conditioned medium
of virally transduced astrocytes (ACM), i.e., MOCK-ACM, GFP-
ACM or that express hTG2 (TG2-ACM), on OPC differentiation
was examined. Differentiation of OPCs involves their progression
through different developmental stages from immature, pre-
myelinating OLGs (Figure 1B, imOLGs, 3 days after initiating
differentiation) toward mature, myelinating OLGs (Figure 1B,
mOLG, 7 days after initiating differentiation). To establish
whether OPCs were differentiated, cells were stained for MBP, a
major myelin specific protein that is imperative for myelination
(Boggs, 2006), and scored as either MBP-positive or MBP-
negative (Figure 1C shows MBP-positive cells without (left) and
with myelin membranes (right)). Exposure to MOCK-ACM,
GFP-ACM, or TG2-ACM at the OPC stage (experimental set
up “I” in Figure 1B) did not significantly affect the relative
percentage of MBP-expressing cells at the immature stage
compared to exposure to non-conditioned medium (Figure 1D).
Similarly, continuous presence of MOCK-ACM, GFP-ACM
or TG2-ACM upon differentiation till the mature OLG stage
(experimental set up “II” in Figure 1B) showed no apparent
effect on differentiation (Figure 1E). The MBP-positive cells
bearing membranous structures spread between the cellular
processes (Figure 1C, arrow) reflect the ability of OLGs to
form myelin membranes. Continuous exposure of TG2-ACM
upon differentiation toward mature OLGs (experimental set up
“II” in Figure 1B) hardly, if at all, affected myelin membrane
formation of mature OLGs compared to non-conditioned
medium, MOCK- or GFP-ACM (Figure 1F), indicating that
hTG2-expressing astrocytes do not modulate OPC differentiation
via secreted factors.
To examine whether hTG2-expressing astrocytes may affect
OPC maturation via signals other than secreted signals, hTG2-
expressing astrocytes and MOCK-transduced astrocytes were
used as a feeding layer in an in vitro myelinating spinal
cord culture (Sorensen et al., 2008). Subsequent analysis of
the percentage of myelinated axons, as assessed with a double
labeling of MBP and the axonal marker neurofilament-H (NF;
Figure 2A), revealed that hTG2 expression in astrocytes slightly,
but not significantly, enhanced the percentage of myelinated
axons by approximately 60% (Figure 2B; p = 0.365). Western
blot analysis showed that hTG2 is hardly detected in hTG2-
expressing astrocyte conditioned medium (ACM) (data not
shown). Therefore, to exclude the possibility that astrocyte
secreted TG2 levels were simply too low or were taken up
by other cells in these myelinating culture set-up, cells were
also treated with recombinant gpTG2. Continuous exposure
of exogenous gpTG2 to spinal cord cultures with a control
astrocyte feeding layer at the time of OPC differentiation, i.e.,
from 12 div onward, increased axonal myelination (Figure 2C)
by approximately 250%. This result, however, did not reach
significance due to variability between the different experiments
(Figure 2D; p = 0.078). Hence, hTG2-rexpressing astrocytes
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FIGURE 1 | Astrocyte-conditioned medium from human TG2 expressing cells does not significantly affect OPC maturation. (A) Wild-type human TG2 (LV TG2), GFP
and empty vector (MOCK) were lentivirally expressed in astrocytes and subjected to western blot analyses. Note that lentiviral expression of wild type human TG2 (LV
TG2) in primary rat astrocytes results in an additional band indicative of the human TG2 (hTG2, arrow), which has a slightly higher molecular weight than endogenous
rat TG2 (rTG2; 78 kDa, arrowhead). (B–F) Schematic representation of the experimental set up is shown in B. Astrocyte conditioned medium (ACM) derived from
lentivirally transduced astrocytes (MOCK, GFP or LV TG2) is directly added to oligodendrocyte progenitor cells (OPCs, monocultures) and analyzed at the immature
oligodendrocyte stage (imOLG, “I,” D) or added both at the OPC stage and the imOLG stage and analyzed at the mature OLG stage (mOLG, “II,” E,F). OPC
differentiation (D,E) and myelin membrane formation (F) are, respectively, assessed as the percentage of myelin basic protein (MBP)-positive cells and the
percentage of myelin membrane bearing MBP-positive cells. Representative images of MBP (myelin marker, red)-positive cells without (left) and with myelin
membranes (right, arrow) are shown in C. Scale bar is 100 µm. Data are shown as mean + SEM, calculated as average percentage compared to OPCs that
received non-conditioned medium (CTRL), which was set to 100% in each independent experiment (n = 4). The percentage of MBP-positive cells in control cells is
1.6 ± 0.2% at the imOLG stage (D) and 16.7 ± 0.2% at the mOLG stage (E), the percentage of myelin membranes at the mOLG stage is 35.6 ± 18.0% (F).
Statistical analyses were performed using a one-sample t-test (not significant).
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FIGURE 2 | Astrocyte-derived human TG2 has no significant effect on myelination in spinal cord cultures. (A,B) Wild-type human TG2 (hTG2) and empty vector were
lentivirally expressed in astrocytes (LV TG2 and MOCK, respectively) which were used as an astrocyte feeding layer in myelinating spinal cord cultures. Myelination
was measured as percentage of myelinated axons, visualized with myelin basic protein (MBP, myelin marker, green) of total neurofilament (NF, red)-positive axons at
26–28 days in vitro. Representative images are shown in A. The relative percentage of myelinated axons in spinal cord cultures with hTG2-expressing astrocytes to
MOCK treated astrocytes is shown in B (n = 3). (C) Spinal cord cultures on a control astrocyte feeding layer were treated with vehicle (PBS) or with recombinant
guinea pig TG2 (gpTG2, 50 µg/ml every 2 days from day 12 in vitro for 14–16 days). Representative images are shown in C. The relative percentage of myelinated
axons in gpTG2 treated spinal cord cultures compared to vehicle-treated (CTRL) cultures is shown in D (n = 4). Data are shown as mean + SEM, calculated as
average percentage compared to MOCK-transduced (B) or vehicle-treated astrocytes (D, CTRL), which were set to 100% in each independent experiment.
Statistical analyses were performed using a one-sample t-test (not significant). Scale bar is 100 µm.
and exogenously added gpTG2 do not significantly affect the
percentage of myelinated axons in an in vitro myelinating culture
on an astrocyte feeding layer, indicating that astrocyte-derived
TG2 is not likely to affect OPC maturation. However, since we
could not exclude direct developmental stage-dependent effects
of TG2 on OPC differentiation/maturation, we next examined
the effect of recombinant gpTG2 treatment on different stages of
OLG development in monocultures.
Addition of TG2 Has a Distinct
Developmental Stage-Dependent Effect
on OPC Maturation in OLG Monocultures
As the timing of OPC differentiation is important for
remyelination, the effect of exogenous addition of recombinant
gpTG2 on early OPC differentiation was first examined. A single
addition of gpTG2 to OPCs and analyses of the percentage of
MBP-positive cells at the immature OLG stage (experimental set
up “I” in Figure 3A) significantly increased the percentage of
MBP-positive cells by 2-fold (Figure 3B; p < 0.05). This increase
in OPC differentiation was no longer apparent at the mature
OLG stage (experimental set up “II” in Figures 3A,C) indicating
that a transient exposure to gpTG2 at the OPC stage accelerated
differentiation. In addition, gpTG2, when added once at the OPC
stage did not affect myelin membrane formation (Figure 3D). In
contrast, however, when gpTG2 was continuously present during
differentiation, i.e., added to OPCs and re-added to immature
OLGs and analyzed at the mature OLG stage (experimental set up
“III” in Figure 3A), a decrease in MBP-positive cells (Figure 3E;
p< 0.05) and myelin membrane formation (Figure 3F; p< 0.05)
was apparent. This decrease in OPC maturation is likely not due
to an effect of gpTG2 on immature OLGs, as the percentage
of MBP-positive cells and myelin membranes is hardly, if at
all, affected when gpTG2 was only added to immature OLGs
and analyzed at the mature OLG stage (experimental set up
“IV” in Figures 3A,G,H). Hence, exogenous addition of gpTG2
revealed distinct differentiation stage-dependent effects on OPC
differentiation. More specifically, transient exposure of gpTG2
to OPCs accelerated differentiation at the immature OLG stage,
which was lost at the mature OLG stage, while continuous
exposure to gpTG2 from the OPC to mature OLG stage,
decreased OPC maturation.
Addition of TG2 to DRGN-OPC
Co-cultures Increases Myelination
As exogenously added gpTG2 affected OPC differentiation,
we subsequently examined whether exposure to TG2 affects
axonal myelination. OPC-DRGN co-cultures were continuously
exposed to exogenous recombinant gpTG2 2 days after OPCs
were added to DRGNs. At 14 days in co-culture, the percentage
of myelinated axons was significantly increased upon addition of
gpTG2 compared to vehicle-treated co-cultures (Figures 4A,B;
p < 0.05). Remarkably, the number of DAPI-stained cells
present on the DRGNs was increased in gpTG2-treated compared
to control cultures, indicating that gpTG2 may also affect
proliferation and/or survival. To examine whether persistent
expression of endogenous TG2 in cells of the OLG lineage
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FIGURE 3 | Addition of TG2 has a developmental stage-dependent effect on OPC maturation. Exogenous guinea pig TG2 (gpTG2) was added to different
developmental stages of the oligodendrocyte (OLG) lineage. Schematic representation of the experimental set up is shown in A. gpTG2 was added once to
oligodendrocyte progenitor cells (OPCs) and analyzed at the immature OLG (imOLG, “I,” B, n = 5) and mature OLG stage (mOLG, “II,” C,D, n = 5), added both at the
(Continued)
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FIGURE 3 | Continued
OPC stage and the imOLG stage and analyzed at the mOLG stage (“III,” E,F, n = 8), or added at the imOLGs and analyzed at the mOLG stage (“IV,” G,H, n = 5).
OPC differentiation (B,C,E,G) and myelin membrane formation (D,F,H) are, respectively, assessed as the percentage of myelin basic protein (MBP)-positive cells and
the percentage of myelin membrane bearing MBP-positive cells. Data are shown as mean + SEM, calculated as average percentage compared to vehicle-treated
(CTRL), which was set to 100% in each independent experiment. The percentage of MBP-positive cells in vehicle-treated cells is 6.3 ± 1.6% at the imOLG stage (B)
and 20.8 ± 11.3% at the mOLG stage (C,E,G), the percentage of myelin membranes at the mOLG stage is 40.8 ± 24.4% (D,F,H). Statistical analyses were
performed using a one-sample t-test (∗p < 0.05).
FIGURE 4 | Addition of TG2 to DRGN-OPC co-cultures increases myelination. (A,B) Exogenous guinea pig TG2 (gpTG2, 25 µg/ml every 3 days from day 2 in vitro
for 11 days) was added to dorsal root ganglion neurons-oligodendrocyte progenitor cell (DRGN-OPC) co-cultures. Myelination was measured as percentage of
myelinated axons, visualized with myelin basic protein (MBP, myelin marker, green) of total neurofilament (NF, red)-positive axons 14 days in co-culture. Nuclei are
visualized with DAPI (blue). Representative images are shown in A, and the relative percentage of myelinated axons in gpTG2-treated DRGN-OPC co-cultures to
vehicle-treated (CTRL) co-cultures is shown in B (n = 3). (C,D) Wild-type human TG2 (hTG2) was lentivirally (LV TG2) overexpressed in OPCs, and plated onto
DRGNs. The extent of myelination was analyzed at 14 days in co-culture. Representative images are shown in C, and the relative percentage of myelinated axons in
DRGN-OPC co-cultures with hTG2-expressing OPCs to MOCK OPCs is shown in D (n = 3). Data are shown as mean + SEM, calculated as average percentage
compared to vehicle-treated (B, CTRL) or MOCK-transduced OPCs (D), which were set to 100% in each independent experiment. Statistical analyses were
performed using a one-sample t-test (∗p < 0.05). Scale bar is 100 µm.
affects axonal myelination, OPCs were lentivirally transduced
with human wild-type TG2 (LV TG2) or empty vector (MOCK)
and subsequently plated onto DRGNs. At 14 days in co-culture,
a similar percentage of myelinated axons of DRGNs in co-culture
with TG2-overexpressing and MOCK-transduced OPC were
observed (Figures 4C,D), indicating that persistent expression
of TG2 in cells of the OLG lineage does not result in enhanced
myelination of axons at the end of myelination. To assess whether
persistent endogenous expression of TG2, similar to addition of
exogenous gpTG2, may only accelerate OPC differentiation, the
effect of lentivirally expression of hTG2 on OPC maturation was
examined next in OLG monocultures.
Sustained TG2 Overexpression in OLG
Lineage Cells by Lentiviral Transduction
Accelerates (Early) Differentiation
We have previously shown that OPCs express TG2, while TG2
is almost not expressed in immature and mature OLGs (van
Strien et al., 2011a). To assess whether persistent expression of
TG2 in cells of the OLG lineage affects OPC differentiation,
OPCs were lentivirally transduced with wild-type human TG2
(LVTG2) or empty vector (MOCK) and allowed to differentiate.
Persistent expression of hTG2 in immature and mature OLGs was
confirmed by western blotting (Figures 5A,B, respectively, see
Supplementary Figure 2 for full blots). Consistent with previous
observations (van Strien et al., 2011a), MOCK-transduced
immature and mature OLGs showed hardly any endogenous rat
TG2 band at 78 kDa, whereas hTG2-transduced cells expressed
human TG2 (Figures 5A,B, arrow). Strikingly, upon expression
of hTG2, also the expression of endogenous rat TG2 appeared and
remained during OPC differentiation (Figures 5A,B, arrowhead).
Moreover, hTG2 overexpressing OPCs significantly increased the
percentage of MBP-positive cells when analyzed at the immature
OLG stage (Figure 5C; p < 0.001), whereas the percentage of
MBP-positive cells at the mature OLG stage was not significantly
affected (p = 0.608; Figure 5D). Of note, the total number of
DAPI-stained cells appeared similar at all conditions. Myelin
membrane formation, however, was slightly, but significantly
increased at the mature OLG stage in hTG2-expressing cells
compared to MOCK-transduced cells (Figure 5E; p < 0.01).
Thus, our findings revealed that persistent expression of TG2 in
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FIGURE 5 | Sustained TG2 expression accelerates (early) OPC differentiation and increases myelin membrane formation. Wild-type human TG2 (LV TG2) and empty
vector (MOCK) were lentivirally expressed in oligodendrocyte progenitor cells (OPCs) and subjected to western blot analyses (A,B) or myelin basic protein (MBP)
immunocytochemistry (C–E) at the immature (A,C) and mature (B,D,E) oligodendrocyte (imOLG and mOLG, respectively) stage. Note that lentiviral expression of
wild type human TG2 (LV TG2) in OPCs results in sustained expression of TG2 (A,B, arrow) and rat TG2 (A,B, arrowhead) upon differentiation. Actin serves as a
loading control (A,B). OPC differentiation (C,D) and myelin membrane formation (E) are, respectively, assessed as the percentage of MBP-positive cells and the
percentage of myelin membrane bearing MBP-positive cells. Data are shown as mean + SEM, calculated as average percentage compared to MOCK-transduced
OPCs, which was set to 100% in each independent experiment (C, n = 8, D,E, n = 5). The percentage of MBP-positive cells in MOCK-transduced cells is
8.7 ± 10.3% at the imOLG stage (C) and 24.9.7 ± 9.9% at the mOLG stage (D), the percentage of myelin membranes at the mOLG stage is 38.9 ± 25.7.0% (E).
Statistical analyses were performed using a one-sample t-test (∗∗p < 0.01 and ∗∗∗p < 0.001).
cells of the OLG lineage accelerated early OPC differentiation. As
TG2 is beneficial for early OPC differentiation, we next examined
whether TG2 is present in cells of the OLG lineage in MS lesions.
TG2 Is Not Present in OPCs in MS
Lesions, but Is Found in OPCs During
Human Cerebellar Development
To determine whether cells of the OLG lineage contain
TG2 in MS lesions, a double labeling of TG2 with the OLG
lineage marker Olig2 was performed in chronic active and
remyelinating MS lesions. Loss of PLP immunoreactivity
confirmed ongoing demyelination at the edge of chronic
active lesions (Figure 6A), while small PLP-positive myelin
fibers likely reflected remyelination in lesions (Figure 6B).
The abundant presence of MHC-II-positive microglia in
chronic active lesions was evident (Figure 6C) which was
less pronounced in remyelinating lesions (Figure 6D). TG2
immunoreactivity was present in blood vessels which is a well
known localization (van Strien et al., 2011c, 2015; Chrobok
et al., 2019), but was virtually absent from Olig2-positive
OLG lineage cells in chronic active (Figure 6E) and in
remyelinating MS lesions (Figure 6F). To examine whether TG2
is expressed in differentiating human OPCs, we studied TG2
immunoreactivity in OPCs during developmental myelination
of the human brain. Interestingly, TG2 immunoreactivity
was observed in platelet-derived growth factor receptor
alpha (PDGFRα)-positive OPCs (indicated by arrows in
Figure 6G) in the developing human cerebellum, at gestational
week 28. Hence, while OPCs in MS lesions do not show
TG2 immunoreactivity, TG2 is present in OPCs during
human cerebellar development, indicating that at the onset
of normal OPC differentiation, TG2 expression is likely
induced by local cues. Given that Transglutaminase expression
and activity is commonly detected both in diseased tissues
with inflammation and cells with inflammatory stress
(Kuncio et al., 1998; Johnson et al., 2001; Kim, 2006), and
TG2 expression is regulated by inflammatory mediators
(van Strien et al., 2011b; Espitia Pinzón et al., 2017a),
we next examined the effect of inflammatory mediators
that are present in MS lesions on TG2 expression in OPCs
and immature OLGs.
IFN-γ Increased and Sustained TG2
Expression in OLG Lineage Cells, Which
Did Not Correlate With Enhanced
Differentiation
As the pro-inflammatory cytokines, TNF-α, IFN-γ, and IL-
1β are present in MS lesions (Codarri et al., 2010; Mendiola
and Cardona, 2018) and influence OPC maturation (Xie et al.,
2016; Valentin-Torres et al., 2018) and therefore remyelination,
we next analyzed whether these cytokines may modulate
TG2 expression in OPCs. OPCs were therefore exposed to
these cytokines for 48 h and allowed to differentiate for
3 days in the absence of cytokines (Figure 7A). Western
blot analyses revealed that 48 h-exposure to IFN-γ, and
to a lesser extent to TNF-α, but not to IL-1β, increased
TG2 expression (Figures 7B,C; TNF-α, p < 0.05; IFN- γ,
p = 0.001, for full blot of Figure 7B see Supplementary
Figure 3A). Interestingly, the enhanced TG2 expression in
cytokine-treated OPCs was sustained in IFN-γ-treated OPCs,
i.e., the increased TG2 expression was still apparent in
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FIGURE 6 | TG2 immunoreactivity is not present in OPCs in MS lesions, but is
found in OPCs during human cerebellar development. Immunohistochemical
stainings were performed for the myelin marker proteolipid protein (PLP) and
for MHC-II positive monocytes/macrophages or microglia in chronic active
lesions (A,C, respectively) and in remyelinating lesions (B,D, respectively).
Immunohistochemical double labeling of TG2 (gray) and Olig2 (pink) was
performed in chronic active lesions (E) and remyelinating MS lesions (F)
(n = 3). Cell nuclei were stained by haematoxylin (blue) in PLP and MHC-II
labeled sections (A–D). Scale bar: 100 µm. Immunofluorescent double
labeling of TG2 (red) and the OPC marker platelet-derived growth factor
receptor (PDGFR)α (green) (G, arrows) in white matter of developing human
cerebellum at gestational week 28. Scale bar: 10 µm.
immature OLGs that were differentiated in the absence
of cytokines (Figures 7A,D,E; p < 0.01, for full blot of
Figure 7D see Supplementary Figure 3B), whereas TG2
expression decreased in TNF-α- or IL-1β-treated OPCs upon
differentiation (Figures 7A,D,E; p < 0.05 for both conditions).
To reveal whether the cytokine-enhanced increase in TG2
expression affects OPC differentiation, cytokine-exposed OPCs
were left to differentiate without the presence of cytokines,
since prolonged cytokine treatment can lead to cytotoxicity
in OLGs (Robbins et al., 1987; Vartanian et al., 1995).
Upon differentiation toward the immature OLG stage, the
percentage of MBP-positive cells was slightly, but non-
significantly, increased in TNF-α-, IFN-γ-, and IL-1β-exposed
OPCs (Figure 7F). Hence, our results revealed that the for
MS relevant inflammatory mediators IFN-γ, and to a lesser
extent TNF-α, increased TG2 expression in OPCs, though no
apparent correlation between cytokine-induced TG2 expression
and increased OPC differentiation at the immature OLG stage
exists, as was observed upon sustained expression of hTG2 in
OLGs (Figure 5). Therefore, enhanced TG2 expression induced
by inflammatory mediators is not sufficient to accelerate early
OPC differentiation.
DISCUSSION
In previous work, we demonstrated that TG2 expression in
OPCs is downregulated upon differentiation and that, in the
absence of TG2, remyelination is delayed upon cuprizone-
induced demyelination (van Strien et al., 2011a), which led to
our hypothesis that TG2 promotes OPC maturation. Our present
findings indicate that early OPC maturation is accelerated by
both endogenous and exogenously supplied TG2, while factors
derived from hTG2-expressing astrocytes do not significantly
affect OPC maturation and myelination. Moreover, we found
TG2 immunoreactivity in human OPCs during development,
but not in cells of the OLG lineage that are present in
chronic active and remyelinating MS lesions. Interestingly, TG2
expression in OPCs was enhanced upon exposure to IFN-γ,
and sustained in immature OLGs, but did not correlate with an
increase in OPC maturation. Thus, while TG2 expression and
exposure promotes early OPC differentiation under physiological
developmental circumstances, IFN-γ, although enhancing TG2
expression, may interfere with (accelerated) OPC differentiation
in a TG2-independent manner. In addition, the absence
of TG2 in cells of the OLG lineage in MS lesions may
contribute to their quiescence, and therefore development of
means to induce TG2 expression in local OPCs may be of
therapeutic interest.
Astrocytes, when activated upon demyelination of the CNS,
transiently secrete soluble factors, such as growth factors and
cytokines (Wiese et al., 2012) and deposit ECM proteins, such
as fibronectin and hyaluronan, that prevent OPC maturation
(Back et al., 2005; Stoffels et al., 2013b). We have previously
shown that astrocytes, present in demyelinating MS lesions, do
express TG2 and can interact with ECM proteins, including
fibronectin (van Strien et al., 2011b,c; Espitia Pinzón et al.,
2017a,b). In addition, we found extracellular astrocyte-associated
TG2, i.e., in extracellular deposits and on the cell-surface
of astrocytes, even under control conditions (van Strien
et al., 2011b; Espitia Pinzón et al., 2017a). In the present
study we, therefore, questioned whether astrocyte-derived TG2
may have an effect on OPC maturation. We observed that
secreted factors derived from hTG2-expressing astrocytes, as
well as direct contact with hTG2-expressing astrocytes did
not lead to a significant alteration in OPC differentiation
or myelination of axons. However, the levels of total TG2
in hTG2-expressing astrocytes do not increase endogenous
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FIGURE 7 | IFN-γ increases and sustains TG2 expression in OLG lineage cells, which does not correlate with enhanced differentiation. Schematic representation of
the experimental set up is shown in A. Oligodendrocyte progenitor cells (OPCs) were left untreated (CTRL) or treated for 48 h with IFN-γ, TNF-α or IL-1β and
subjected to western blot analyses (B,C) or allowed to differentiate for 3 days to immature oligodendrocytes (imOLG) in the absence (A,D) of these cytokines and
subjected to western blot analyses (D,E) or myelin basic protein (MBP) immunocytochemistry (F). Representative blots are shown in B,D, quantification in C,E.
Western blot data are quantified by normalizing the optical densities of TG2 against actin, which serves as loading control. OPC differentiation (F) is assessed as the
percentage of MBP-positive cells. Data are shown as mean + SEM, calculated as average percentage compared to control OPCs, which was set to 100% in each
independent experiment (C, n = 7, E, n = 4, F, n = 4). The percentage of MBP-positive cells at the imOLG stage in control cells is 20.7 ± 15.4% in F. Statistical
analyses were performed using a one-sample t-test (∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001).
TG2 levels and hTG2 was not released at detectable levels
and therefore no effect was found. Of note, in contrast to
astrocytes in the cuprizone model (Skripuletz et al., 2013;
Tameh et al., 2013) and in MS lesions, (Williams et al.,
2007; Gudi et al., 2014; Lassmann, 2014), the hTG2-expressing
astrocytes used in the present study were not subjected to
an inflammatory environment which could have implications
for their function. Previous work revealed that upon exposure
to inflammatory mediators, e.g., TNF-α and IL-1β, astrocyte-
derived TG2 can contribute to ECM rearrangement, and
possibly subsequent scar formation (Espitia Pinzón et al.,
2017a). Inflammatory activation of astrocytes might therefore
be necessary to reveal an effect of astrocyte-derived TG2 on
OPC maturation. Alternatively, microglial-derived TG2 may
play a role in OPC proliferation/myelination, as recently
shown (Giera et al., 2018). It should be noted, however,
that in the study by Giera et al. (2018) the presence
of TG2 in microglia in vivo was not visualized which
is important as we only observed TG2 in astrocytes in
the mouse cuprizone model (Espitia Pinzón et al., 2017b)
and less TG2 protein in cultured rat microglia than in
astrocytes (Espitia Pinzón et al., 2017a). Of note, upon hTG2
expression, TG2 is not overexpressed, indicating that astrocytes
reduced their endogenous TG2 levels. Therefore, to firmly
conclude that astrocyte-derived TG2 does not affect OPC
differentiation or myelination, downregulation of astrocytic TG2
should be considered.
As proof of principle, we observed that, when adding a
relatively high dose of exogenous TG2 to our cultures, this
affected OPC maturation. More specifically, a single exposure of
OPCs to TG2 accelerated their subsequent differentiation and
the extent of axonal myelination is increased in TG2-treated
DRGN-OPC co-cultures. In contrast, continuous exposure
of OPCs to TG2 decreased OPC differentiation and myelin
membrane formation. Of relevance, microglia-derived TG2
promotes OPC proliferation and remyelination in the presence
of laminin via adhesion G-protein coupled receptor (ADGRG1)
signaling (Giera et al., 2018). While laminin is absent in
monocultures, DRGNs express laminin, and therefore, it is
tempting to suggest that the opposite effect of continuous
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TG2 treatment in mono- and co-cultures may be due to
DRGN-derived laminin. In fact, the number of cells appeared
increased upon gpTG2 addition, indicating that DRGN-derived
laminin and exposure to TG2 may increase OPC proliferation,
resulting in more mature myelinating OLGs at the endpoint
of myelination. Also, endogenous TG2 overexpression in
OPCs enhanced the percentage of MBP-positive cells at early
OPC differentiation; while the percentage of MBP-positive
cells of TG2-overexpressing and MOCK-transduced cells were
similar at the endpoint of OPC differentiation. Accordingly,
TG2-overexpressing OPCs did not affect the number of
myelinated axons in DRGN-OPC co-cultures at the endpoint
of myelination. This indicates that endogenousTG2 is involved
in the timing of OPC differentiation. These findings are
consistent with our previous observation that when TG2
activity is pharmacologically inhibited, the differentiation of
OPCs into myelin-forming OLGs is dramatically delayed (van
Strien et al., 2011a). Co-labeling studies revealed that TG2
immunoreactivity was lacking in Olig2-positive OPCs/OLGs
in chronic active and in remyelinating MS lesions. Howeover,
in the developing human cerebellum, TG2 was present in
PDGFRα-positive OPCs, while we never observed cellular
TG2 immunoreactivity in adult NAWM, apart from blood
vessels (van Strien et al., 2011c, 2015; Chrobok et al., 2019).
These data suggest that in human brain TG2 expression is
transiently present in OPCs, during physiological, developmental
differentiation and not in OPCs during adulthood, irrespective
of the presence of inflammatory activity. Of relevance, in vitro
studies indicate that TG2 protein and activity is absent
in mature OLGs (van Strien et al., 2011a) which may be
part of normal brain development. Hence, it is tempting to
suggest that finding means to increase TG2 expression in
OPCs may trigger their differentiation in MS lesions. On
the other hand, it is good to take into consideration that
TG2 is not essential for OPC differentiation, as remyelination
does proceed, although delayed, as shown in TG2 –/– mice
(van Strien et al., 2011a).
Increased TG2 expression is often detected in cells under
pathological conditions in which inflammation is involved
(Kim, 2006; van Strien et al., 2011b; Espitia Pinzón et al.,
2017a). In line with this the pro-inflammatory cytokines IFN-γ
and to a lesser extent TNF-α significantly increased TG2
expression in OPCs. In IFN-γ -treated OPCs, the increased
TG2 expression sustained during OPC differentiation in the
absence of IFN-γ. Although sustained TG2 overexpression
in OPCs markedly accelerated OPC differentiation, OPC
differentiation was only slightly enhanced in IFN-γ and TNF-
α-treated OPCs. In contrast, IL-1β treatment of OPCs had
no effect on TG2 expression, while OPC differentiation was
not significantly increased. IL-1β -induced OPC differentiation
has been described by others (Vela et al., 2002) though
inhibition of OPC maturation has also been reported (Xie
et al., 2016). Our results therefore revealed no apparent
relationship between modulation of TG2 expression by pro-
inflammatory cytokines and early OPC differentiation, i.e., in
immature OLGs. This may be a result of activation of a more
prominent TG2-independent pathway upon stimulation with
IFN-γ and TNF-α or their interference with signaling pathways
downstream of TG2.
IFN-γ, TNF-α, and IL-1β are pro-inflammatory cytokines that
are present in MS lesions (Vartanian et al., 1995; Arnett et al.,
2001; Mason et al., 2001; Codarri et al., 2010). In astrocytes
and microglia, TG2 can be induced by different inflammatory
mediators, including combinations of cytokines, such as IFN-γ
in combination with TNF-α or IL-1β and TNF-α in combination
with IL-1β (Monsonego et al., 1997; Takano et al., 2010; van
Strien et al., 2011b; Espitia Pinzón et al., 2017a). In monocytes,
IFN-γ is also an inducer of TG2 production (Mehta et al., 1985,
1987). Recent observations showed that of a range of cytokines
applied to human monocytes, IL-4 was actually the most
prominent one to induce TG2 expression in human monocytes
and macrophages (Gratchev et al., 2005; Yamaguchi et al., 2016;
Sestito et al., 2017). In OPCs, however, we found no increase
in TG2 expression after treatment with IL-4 (data not shown,
n = 3). Also, various combinations of IFN-γ with TNF-α or IL-
1β had no additional effect on TG2 production in OPCs (data not
shown). The responsiveness of glial cells to various inflammatory
mediators can be explained by the presence of cytokine receptors
(Cannella and Raine, 2004) and inflammatory factor-related
response elements in the promotor region of the TG2 gene
(Ikura et al., 1994; Kuncio et al., 1998; Gundemir et al., 2012),
including NF-κB (nuclear factor-kappa B), a transcription factor
involved in the regulation of expression of many inflammatory
mediators (Ientile et al., 2015). The transcription of TG2 is
therefore differently regulated during inflammation in these
glial cells and represents different functions of these cells
during inflammation. Monocyte-, macrophage- and astrocyte-
derived TG2 is involved in various processes contributing to
inflammation, such as adhesion and extravasation, monocyte
differentiation into macrophages, efferocytosis and astrogliosis
(Hostenbach et al., 2014; Chrobok et al., 2016; Espitia Pinzón
et al., 2017a). TG2 in OPCs could therefore have a different
function, which is not involved in processes contributing to
inflammation but rather in intracellular processes that contribute
to their differentiation. Our previous observations indicate that
TG2 affects RhoA GTPase activity (van Strien et al., 2011a).
Rho GTPases are essential in cytoskeleton rearrangements,
and consequently the outgrowth of OLG processes (Czopka
et al., 2009). Alternatively, TG2 can signal through ADGRG1,
in OPCs in the presence of the ECM protein laminin.
Signaling by TG2/laminin to ADGRG1 on OPCs improved
remyelination in two murine models of demyelination (Giera
et al., 2018). Interference of inflammatory mediators with one
of these pathways may lead to the observed uncoupling of TG2
expression and OPC differentiation (Geras-Raaka et al., 1998;
Surin et al., 2002).
Taken together, our data indicate that TG2 transiently
appears in developing OPCs and promotes early OPC
differentiation, while its absence in OPCs in MS lesions,
irrespective of the presence of inflammatory activity, may
contribute to remyelination failure (Franklin and ffrench-
Constant, 2008; Kuhlmann et al., 2008). We therefore propose
that development of means that stimulate TG2 expression and
function in OPCs may represent a novel therapeutic strategy
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to improve differentiation of OPCs in MS and thereby contribute
to remyelination.
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